Stallergenes Greer Ltd is a United States-based holding company. The Company is a healthcare company. Its engaged in the diagnosis and treatment of allergies through the development and commercialization of allergen immunotherapy products and services. It also engaged in distribution of products and services.

Employees

Sector

Pharmaceuticals

More about the company

Real-time Euronext Paris			5-day change	1st Jan Change
- ^EUR	-.--%		+0.14%	+29.68%

07-17	Stallergenes Greer Ltd Reports Earnings Results for the Full Year Ended December 31, 2025	CI
05-05	Stallergenes Greer Ltd Announces Termination of Nicola Lamacchia as Director on April 30, 2026	CI

Market Cap	724M 843M 678M 621M 1.17B 80.56B 1.17B 8.03B 3.14B 40.6B 3.17B 3.1B 134B	P/E 2024 *	-	P/E 2025	-
Enterprise Value	724M 843M 678M 621M 1.17B 80.54B 1.17B 8.03B 3.14B 40.59B 3.17B 3.1B 134B	EV / Sales 2024 *	-	EV / Sales 2025	-
Free-Float	-	Yield 2024 *	-	Yield 2025	-

07-17	Stallergenes Greer Ltd Reports Earnings Results for the Full Year Ended December 31, 2025	CI
05-05	Stallergenes Greer Ltd Announces Termination of Nicola Lamacchia as Director on April 30, 2026	CI
05-05	Stallergenes Greer Ltd Appoints Andreas Christian Amrein as Director on April 30, 2026	CI
07/10/25	Stallergenes Greer Ltd Reports Earnings Results for the Full Year Ended December 31, 2024	CI
08/04/25	Stallergenes Greer Ltd Announces Termination of Nunzio Michele Antonelli as Director	CI
09/01/25	European Commission Approves the Extension of the Indication of Palforzia to the Treatment of Toddlers with Confirmed Peanut Allergy	CI
01/10/24	Stallergenes Greer Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	CI
11/07/23	Nestle Reportedly May Sell Peanut Allergy Therapy to Stallergenes	CI
25/05/23	Stallergenes Greer Ltd Initiates European Paediatric Phase III Study with Staloral Birch	CI
06/05/22	Stallergenes Greer Ltd Reports Earnings Results for the Full Year Ended December 31, 2021	CI
17/01/22	Stallergenes Greer Strengthens Precision Medicine Approach in Allergen Immunotherapy with Imperial College London Research Collaboration	CI
26/10/21	Stallergenes Greer and Aptar Pharma Announce Partnership to Develop Novel Connected Device for Allergen Immunotherapy Treatment Delivery	CI
09/07/21	Stallergenes Greer and Alyatec Announce Research Collaboration to Advance Precision Medicine in Allergen Immunotherapy	CI

25/01/18	Stallergenes Greer : comments on share price movement	PU
04/10/17	Stallergenes Greer : 04/10/2017 - Director/PDMR Shareholding. Released October 4, 2017	PU
03/10/17	Stallergenes Greer : 03/10/2017 - Director/PDMR Shareholding	PU
19/06/17	Stallergenes Greer : First real-world evidence shows long term benefits of sublingual immunotherapy to control allergic rhinitis and potentially prevent allergic asthma	PU
03/05/17	Stallergenes Greer : NOTIFICATION TO SHAREHOLDERS OF ANNUAL GENERAL MEETING ON 8 JUNE 2017	PU

Stallergenes Greer Stock

Stocks

STAGR

GB00BZ21RF93

Pharmaceuticals

Valuation : Stallergenes Greer

Latest news : Stallergenes Greer

Press Releases : Stallergenes Greer

News in other languages : Stallergenes Greer

Managers and Directors : Stallergenes Greer

Specialty & Advanced Pharmaceuticals

Financials

Company Profile

06/11/23	AB Science : Le secteur pharmaceutique signe un accord de branche sur la transition écologique
17/05/19	Stallergenes Greer : radiation du titre ce jour
17/05/19	Stallergenes Greer : fin de partie à la Bourse de Paris
14/05/19	EN DIRECT DES MARCHES : EDF, Vinci, Ipsen, Europlasma, Erytech, Bayer, Volkswagen...
14/05/19	Trump, la carotte après le bâton

Manager	Title	Age	Since
Andreas Amrein CEO	Chief Executive Officer	-	01/04/2025
Amer Jaber COO	Chief Operating Officer	-	01/01/2019
Daniel Smith CTO	Chief Tech/Sci/R&D Officer	-	11/04/2016

Director	Title	Age	Since
Francesco Pietro Crispino BRD	Director/Board Member	-	07/05/2019
Nicola Lamacchia BRD	Director/Board Member	-	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
STALLERGENES GREER	-.--%	+0.14%	-	-	0
MERCK & CO., INC.	-2.33%	+0.37%	+77.88%	+35.69%	369B
MERCK KGAA	-0.14%	+1.52%	+30.22%	-13.60%	70.96B
HALOZYME THERAPEUTICS, INC.	-0.13%	+0.75%	+46.11%	+150.46%	12.14B
KYOWA KIRIN CO., LTD.	+1.74%	+2.86%	+3.80%	+1.10%	8.6B
SK BIOPHARMACEUTICALS CO., LTD.	-2.31%	-0.94%	-16.02%	-0.35%	4.99B
YUHAN CORPORATION	-1.19%	+4.65%	-28.68%	+15.69%	4.46B
BETTA PHARMACEUTICALS CO., LTD.	+1.34%	-11.74%	-32.42%	+8.76%	3.22B
SUPERNUS PHARMACEUTICALS, INC.	-1.54%	-6.87%	-1.95%	+40.78%	2.57B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+2.75%	-4.05%	-15.05%	-3.95%	2.2B
Average	+0.17%	-0.60%	+7.10%	+26.06%	47.81B
Weighted average by Cap.	+0.88%	+0.48%	+65.09%	+29.76%

	2023	2024 *
Net sales	-	-
Net income	-4.51M -5.25M -4.22M -3.86M -7.28M -501M -7.3M -49.95M -19.53M -253M -19.71M -19.28M -836M	-
Net Debt	24.35M 28.37M 22.8M 20.87M 39.32M 2.71B 39.44M 270M 106M 1.37B 107M 104M 4.52B	-